Any medication that does something useful can also cause side effects. Peptides are no exception. Some are common and temporary. Some are rare but serious. And for some peptides, we're honest that the human data is limited.
Here's what the evidence shows, organized by peptide type. No hedging. No minimizing. Just what you should expect and what should prompt a call to your doctor.
Universal: Injection Site Reactions
This applies to any injectable peptide. You're putting a needle through your skin. Your body sometimes reacts.
- Redness at the injection site — common, temporary, typically resolves in 30 minutes to a few hours
- Mild swelling or itching — common, usually mild
- Small bruise — occasional, depends on technique and individual tendency to bruise
- Mild pain or stinging during injection — varies by peptide formulation, usually minimal with a 30-gauge needle
Injection site reactions are the most common side effect across all peptide types. They're almost always mild and diminish as you develop better injection technique. Rotating injection sites (alternating between left and right abdomen, for example) helps.
GLP-1 Peptides (Semaglutide, Tirzepatide)
GLP-1 receptor agonists have the most extensive side effect data because they've been through large Phase III clinical trials with thousands of participants.
Common side effects (experienced by 10%+ of patients)
- Nausea: The most common side effect. Affects 20–44% of patients depending on the specific drug and dose. Typically worst during dose escalation and improves over 4–8 weeks.
- Diarrhea: 15–30% of patients. Usually mild and temporary.
- Constipation: 10–24% of patients. Increasing water and fiber intake helps.
- Vomiting: 8–24% of patients. More common at higher doses and during titration.
- Abdominal pain: 10–20% of patients. Usually mild cramping, not severe.
- Reduced appetite: This is both a side effect and the intended effect. Some patients experience appetite reduction more strongly than expected initially.
Less common side effects (1–10%)
- Headache
- Fatigue
- Dizziness
- Acid reflux / GERD
- Hair thinning — associated with rapid weight loss rather than the medication itself
Rare but serious (less than 1%)
- Pancreatitis: Inflammation of the pancreas. Signs: severe abdominal pain that radiates to the back, nausea, vomiting. Rare but serious — call your doctor immediately.
- Gallbladder problems: Rapid weight loss increases gallstone risk regardless of method. May require treatment.
- Thyroid C-cell tumors: Seen in animal studies. Theoretical risk in humans. Contraindicated if you have personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
The good news: GI side effects are dose-dependent and typically temporary. Slow titration — starting at the lowest dose and increasing gradually every 4 weeks — is the single most effective way to minimize them. Most patients who experience nausea in the first 2 weeks find it resolves significantly by week 6–8.
Sermorelin
Sermorelin has one of the mildest side effect profiles among therapeutic peptides. Because it works through your body's natural feedback system (stimulating the pituitary rather than injecting synthetic hormone), the safety ceiling is built in.
Common
- Injection site reactions: Redness, mild swelling — the most common complaint
- Facial flushing: Warm feeling in the face shortly after injection. Temporary, resolves within minutes. More common with faster injection speed.
Uncommon
- Headache
- Dizziness
- Sleepiness or vivid dreams — sermorelin enhances deep sleep, which can mean more vivid dreaming initially
Rare
- Joint pain or swelling: If growth hormone levels increase too quickly. Usually manageable with dosage adjustment.
- Fluid retention: Mild, if it occurs at all. Much less common than with direct HGH injection.
Most patients tolerate sermorelin well. The side effect profile is noticeably milder than synthetic HGH because your pituitary gland naturally limits how much growth hormone is produced — you can't accidentally over-stimulate it.
BPC-157
Here's where we need to be especially honest: human side effect data for BPC-157 is limited.
BPC-157 has extensive animal research showing a favorable safety profile. In rats, even at doses far exceeding therapeutic levels, serious toxicity hasn't been observed. But rats aren't humans, and preclinical safety doesn't automatically translate to clinical safety.
Reported (from clinical observation, not large trials)
- Injection site reactions: Standard for any injectable
- Mild nausea: Occasionally reported, particularly with oral formulations
- Dizziness: Uncommon
What we don't know
- Long-term side effects in humans (studies are short-term)
- Interaction effects with other medications (not systematically studied in humans)
- Effects in specific populations (pregnancy, pediatric, severe renal/hepatic impairment)
Regulatory note: BPC-157 is Category 2, with compounding currently restricted. The limited human safety data is one reason for its regulatory classification. If your physician recommends it, they should be transparent about where the evidence stands.
PT-141 (Bremelanotide)
PT-141 is FDA-approved (as Vyleesi), so we have clinical trial safety data.
Common
- Nausea: The most reported side effect — approximately 40% of patients in trials. Usually mild and temporary.
- Flushing: Warmth and redness, particularly in the face. Common and temporary.
- Headache: Reported by approximately 11% of patients.
- Injection site reactions: Standard for injectables.
Uncommon
- Increased blood pressure: Transient increase observed in trials. Significant for patients with uncontrolled hypertension or cardiovascular disease.
- Skin darkening (hyperpigmentation): PT-141 acts on melanocortin receptors, which can stimulate melanin production. Uncommon but reported.
Contraindications
PT-141 should not be used by patients with uncontrolled hypertension or known cardiovascular disease. It also shouldn't be taken with naltrexone.
NAD+
Injectable / IV
- Flushing and warmth: Very common with IV administration, less common with subcutaneous
- Nausea: Particularly with IV administration if the drip rate is too fast
- Cramping or chest tightness: During IV infusion — resolved by slowing the drip rate
- Injection site reactions: Standard for subcutaneous route
Most NAD+ side effects are related to the rate of administration (IV too fast) rather than the substance itself. Experienced clinics know to control infusion speed to minimize discomfort.
When to Call Your Doctor
Call your physician or care team if you experience any of these:
- Severe or persistent nausea/vomiting that prevents you from eating or drinking for more than 24 hours
- Severe abdominal pain — especially if it radiates to your back (possible pancreatitis)
- Signs of allergic reaction: hives, rash, facial swelling, difficulty breathing, rapid heartbeat
- Signs of injection site infection: increasing redness, warmth, swelling, pus, red streaks, or fever
- Unusual heart palpitations or chest pain
- Yellowing of skin or eyes (jaundice)
- Anything that feels wrong or concerning to you — trust your instincts
This isn't about being paranoid. Most peptide side effects are mild and manageable. But having a physician who monitors your treatment means problems get caught early when they're easy to address. That's the value of legitimate medical oversight — someone is watching your response and adjusting accordingly.
What Monitoring Catches
Regular lab work during peptide therapy serves a specific purpose: catching issues before they become problems.
- Metabolic panel: Monitors kidney and liver function, electrolytes, blood sugar. Ensures the peptide isn't stressing your organs.
- A1C / glucose: Particularly important for GLP-1 patients. Tracks blood sugar improvements and catches hypoglycemia risk.
- IGF-1: For growth hormone peptides like sermorelin. Confirms GH levels are in the therapeutic range — not too low (under-dosed) or too high (over-stimulated).
- Thyroid function: Baseline and periodic monitoring, particularly for GLP-1 patients given the theoretical thyroid risk.
- Lipid panel: Tracks cardiovascular markers. GLP-1s often improve lipid profiles — monitoring confirms it.
- CBC: Basic blood cell counts. Catches any unexpected changes in blood composition.
Your physician uses this data to adjust your protocol, confirm the treatment is working, and ensure safety. It's not optional busywork — it's how responsible peptide therapy is practiced.
Honesty Builds Trust
We'd rather you know every possible side effect upfront than find out about one later and feel misled. Peptide therapy has a favorable safety profile — especially compared to many conventional pharmaceuticals. But "favorable" doesn't mean "zero risk." Every medical treatment involves tradeoffs.
The question isn't "are there side effects?" — there always are. The question is: are the potential benefits worth the potential risks for your specific situation? That's exactly what a physician consultation helps you figure out.